Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

索拉非尼 医学 肝细胞癌 双盲 内科学 安慰剂 相(物质) 肿瘤科 替代医学 病理 有机化学 化学
作者
Ann‐Lii Cheng,Yoon‐Koo Kang,Zhendong Chen,Chao-Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Sheng‐Long Ye,Tsai‐Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,D. Voliotis
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:10 (1): 25-34 被引量:6140
标识
DOI:10.1016/s1470-2045(08)70285-7
摘要

Summary

Background

Most cases of hepatocellular carcinoma occur in the Asia-Pacific region, where chronic hepatitis B infection is an important aetiological factor. Assessing the efficacy and safety of new therapeutic options in an Asia-Pacific population is thus important. We did a multinational phase III, randomised, double-blind, placebo-controlled trial to assess the efficacy and safety of sorafenib in patients from the Asia-Pacific region with advanced (unresectable or metastatic) hepatocellular carcinoma.

Methods

Between Sept 20, 2005, and Jan 31, 2007, patients with hepatocellular carcinoma who had not received previous systemic therapy and had Child-Pugh liver function class A, were randomly assigned to receive either oral sorafenib (400 mg) or placebo twice daily in 6-week cycles, with efficacy measured at the end of each 6-week period. Eligible patients were stratified by the presence or absence of macroscopic vascular invasion or extrahepatic spread (or both), Eastern Cooperative Oncology Group performance status, and geographical region. Randomisation was done centrally and in a 2:1 ratio by means of an interactive voice-response system. There was no predefined primary endpoint; overall survival, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), and safety were assessed. Efficacy analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00492752.

Findings

271 patients from 23 centres in China, South Korea, and Taiwan were enrolled in the study. Of these, 226 patients were randomly assigned to the experimental group (n=150) or to the placebo group (n=76). Median overall survival was 6·5 months (95% CI 5·56–7·56) in patients treated with sorafenib, compared with 4·2 months (3·75–5·46) in those who received placebo (hazard ratio [HR] 0·68 [95% CI 0·50–0·93]; p=0·014). Median TTP was 2·8 months (2·63–3·58) in the sorafenib group compared with 1·4 months (1·35–1·55) in the placebo group (HR 0·57 [0·42–0·79]; p=0·0005). The most frequently reported grade 3/4 drug-related adverse events in the 149 assessable patients treated with sorafenib were hand-foot skin reaction (HFSR; 16 patients [10·7%]), diarrhoea (nine patients [6·0%]), and fatigue (five patients [3·4%]). The most common adverse events resulting in dose reductions were HFSR (17 patients [11·4%]) and diarrhoea (11 patients [7·4%]); these adverse events rarely led to discontinuation.

Interpretation

Sorafenib is effective for the treatment of advanced hepatocellular carcinoma in patients from the Asia-Pacific region, and is well tolerated. Taken together with data from the Sorafenib Hepatocellular Carcinoma Assessment Randomised Protocol (SHARP) trial, sorafenib seems to be an appropriate option for the treatment of advanced hepatocellular carcinoma.

Funding

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
温暖砖头发布了新的文献求助10
刚刚
小旋风发布了新的文献求助20
1秒前
1秒前
1秒前
苏苏完成签到,获得积分10
2秒前
2秒前
yy完成签到 ,获得积分10
2秒前
娜子发布了新的文献求助10
2秒前
白羽清风兮完成签到,获得积分10
2秒前
Gmj发布了新的文献求助10
3秒前
懵懂的飞飞完成签到,获得积分10
3秒前
3秒前
4秒前
ding的应助被李恒采纳,获得10
4秒前
wl完成签到,获得积分10
4秒前
平常的傲旋完成签到 ,获得积分10
5秒前
哈哈哈完成签到,获得积分10
6秒前
Eric发布了新的文献求助10
6秒前
zchhh完成签到 ,获得积分10
7秒前
花样年华发布了新的文献求助10
7秒前
隋玉发布了新的文献求助10
7秒前
7秒前
谨慎枫叶发布了新的文献求助10
8秒前
9秒前
神宝嘎li发布了新的文献求助10
9秒前
英俊的铭的应助被小王采纳,获得10
9秒前
孝择发布了新的文献求助10
9秒前
海边捡贝壳完成签到 ,获得积分10
9秒前
科研小郭发布了新的文献求助30
9秒前
星辰大海的应助被15采纳,获得30
10秒前
搜集达人的应助被大气的嚓茶采纳,获得10
10秒前
体贴鹰发布了新的文献求助10
10秒前
仙八完成签到 ,获得积分10
10秒前
田様的应助被钟梓袄采纳,获得10
11秒前
CipherSage的应助被钟梓袄采纳,获得10
11秒前
hitech的应助被小橘子采纳,获得20
11秒前
爆米花的应助被钟梓袄采纳,获得10
11秒前
Crssss的应助被单纯乘风采纳,获得10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183091
求助须知:如何正确求助?哪些是违规求助? 9572406
关于积分的说明 21825003
捐赠科研通 7779812
什么是DOI,文献DOI怎么找? 3433837
关于科研通互助平台的介绍 2558045
邀请新用户注册赠送积分活动 2480046